Browse > Article
http://dx.doi.org/10.3746/jkfn.2011.40.9.1201

Induction of Apoptosis by Combined-treatment with Genistein and TRAIL in U937 Human Leukemia Cells  

Choi, Yung-Hyun (Department of Biochemistry, College of Oriental Medicine, Department of Biomaterial Control (BK21 Program), Graduate School, Blue-Bio Industry Regional Innovation Center, Dongeui University)
Han, Min-Ho (Department of Biochemistry, College of Oriental Medicine, Department of Biomaterial Control (BK21 Program), Graduate School, Blue-Bio Industry Regional Innovation Center, Dongeui University)
Publication Information
Journal of the Korean Society of Food Science and Nutrition / v.40, no.9, 2011 , pp. 1201-1207 More about this Journal
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed as a potent tool to trigger apoptosis in cancer therapy. However, as many types of cancer cells remain resistant towards TRAIL-induced cytotoxicity, several combined therapy approaches aimed to sensitize cells to TRAIL have been developed. Genistein, a natural isoflavonoid phytoestrogen, has been shown to have anticancer activity by inducing cell cycle arrest at G2M phase as well as apoptosis in various cancer cell lines. In the present study, we showed that treatment with TRAIL in combination with subtoxic concentrations of genistein sensitized U937 human leukemia cells to TRAIL-mediated apoptosis. Combined treatment with genistein and TRAIL effectively activated caspases through Bid truncation (tBid) and down-regulation of cellular caspase-8 (FLICE)-like inhibitory proteinL ($cFLIP_L$). However, the apoptotic effects of co-treatment with genistein and TRAIL were significantly inhibited by specific caspase inhibitors, which demonstrates the important role of caspases in apoptosis induced by genistein and TRAIL. Overall, our results indicate that genistein can potentiate TRAIL-induced apoptosis through down-regulation of $cFLIP_L$ and up-regulation of pro-apoptotic tBid proteins.
Keywords
genistein; TRAIL; U937; apoptosis;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Yang LQ, Fang DC, Wang QR, Yang SM. 2004. Effect of NF-kB, survivin, Bcl-2 and caspase-3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 10: 22-25.   DOI
2 Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. 1999. Yama/CPP32 $\beta$, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
3 Griffith TS, Lynch DH. 1998. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563.   DOI
4 Falschlehner C, Emmerich CH, Gerlach B, Walczak H. 2007. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475.   DOI   ScienceOn
5 Siegelin MD, Siegelin Y, Habel A, Gaiser T. 2009. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett 453: 92-97.   DOI
6 Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. 1998. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31: 184-191.   DOI
7 Choi YH, Lee WH, Park KY, Zhang L. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173.   DOI
8 Choi YH, Zhang L, Lee WH, Park KY. 1998. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol 13: 391-396.
9 Harris P, Ralph P. 1985. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol 37: 407-422.   DOI
10 Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. 2006. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107.   DOI
11 Ouyang G, Yao L, Ruan K, Song G, Mao Y, Bao S. 2009. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol Int 33: 1237-1244.   DOI
12 Zhao R, Xiang N, Domann FE, Zhong W. 2009. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 61: 397-407.   DOI
13 Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL induced apoptosis in cancer. Cancer Gene Ther 12: 228-237.   DOI
14 Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. 2006. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66: 1136-1143.   DOI
15 Nozawa F, Itami A, SarucM, Kim M, Standop J, Picha KS, Cowan KH, Pour PM. 2004. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and genistein is effective in inhibiting pancreatic cancer growth. Pancreas 29: 45-52.   DOI
16 Park SY, Seol DW. 2002. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295: 515-518.   DOI
17 Jin CY, Park C, Cheong J, Choi BT, Lee TH, Lee JD, Lee WH, Kim GY, Ryu CH, Choi YH. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257: 56-64.   DOI
18 Szliszka E, Czuba ZP, Jernas K, Król W. 2008. Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci 9: 56-64.   DOI
19 Bronikowska J, Szliszka E, Czuba ZP, Zwolinski D, Szmydki D, Krol W. 2010. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules 15: 2000-2015.   DOI
20 Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180: 143-150.   DOI
21 Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, Kim WJ, Choi YH. 2009. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20: 713-722.   DOI
22 French LE, Tschopp J. 1999. The TRAIL to selective tumor death. Nat Med 5: 146-147.   DOI
23 Gilliland DG, Jordan CT, Felix CA. 2004. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004: 80-97.   DOI
24 Abramson N, Melton B. 2000. Leukocytosis: basics of clinical assessment. Am Fam Physician 62: 2053-2060.
25 Wiernik PH. 1988. Leukemias and myeloma. Cancer Chemother Biol Response Modif 10: 129-147.
26 Wang S, EI-Deiry SW. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633.   DOI
27 Srivastava RK. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546.   DOI
28 Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. 1999. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753.
29 Aggarwal B, Shishodia S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.   DOI
30 Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. 2006. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 6: 401-407.   DOI